PPAR Research

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Disease and Targeted Treatments


Publishing date
01 Mar 2021
Status
Closed
Submission deadline
16 Oct 2020

Lead Editor

1Harvard Medical School, Boston, USA

2Tongji University, Shanghai, China

3University of Sydney, Westmead, Australia

4Fudan University, Shanghai, China

5Nanjing Medical University, Nanjing, China

This issue is now closed for submissions.
More articles will be published in the near future.

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Disease and Targeted Treatments

This issue is now closed for submissions.
More articles will be published in the near future.

Description

The peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors that regulate the expression of genes. All three PPAR isotypes, PPAR-α, PPAR-β/δ, and PPAR-γ, though expressed in different tissues, play essential roles in the regulation of cellular differentiation, development, metabolism, and tumorigenesis. Many types of medicine exert multiple effects targeted for PPARs in various human diseases, such as thiazolidinediones (TZDs) for restoring insulin sensitivity in type 2 diabetes, and fibrates for reducing cardiovascular events such as coronary heart disease, myocardial infarction, and stroke in type 2 diabetic patients without the use of statins. Given that PPARs are known to play a role in human diseases, the targeted medication of PPARs needs to be developed for appropriate clinical utilisation.

However, adverse effects of current PPAR agonists have been extensively reported. For example, the clinical use of the PPAR-γ agents pioglitazone and rosiglitazone revealed a number of common adverse effects, including weight gain, fluid retention, congestive heart failure, and bone fractures. Thus, the development of tissue-specific agonists may enhance the therapeutic benefits and reduce deleterious effects. Traditional Chinese medicine (TCM) compounds have long been used against metabolic disease and related cardiovascular complications and are an attractive resource in the design of new PPAR agonists to reduce cardiovascular risks.

The aim of this Special Issue is to invite investigators to submit original research articles and review articles that aim to increase the knowledge of PPAR signalling pathways in related diseases and medicines at systematic or tissue levels.

Potential topics include but are not limited to the following:

  • The dominant roles played by PPARs in the development of human metabolic-related diseases, including obesity, type 2 diabetes, cardiovascular diseases, or hepatic steatosis
  • Medicines targeted for PPARs including inhibitors, agonists, antagonists, activators, and modulators for different human diseases
  • Pharmacological and toxicological effects of targeted medicines for PPARs and in-depth exploration of the mechanisms
  • Combined drug therapy for PPAR signalling pathways and related drug screening
  • Drug screening of PPAR activators/inhibitors as novel targeting agents
  • The comparison of PPAR targeted medicines with other targeted drugs
  • The broad exploration of PPAR signalling pathways in human diseases and pharmacotherapeutics
  • Crosstalk between PPAR signalling and other pathways in human diseases and pharmacotherapeutics

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 8864813
  • - Research Article

Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ Facilitates Cell Proliferation in Human Cholesteatoma Keratinocytes

Chen Zhang | Yang-Wenyi Liu | ... | Bing Chen
  • Special Issue
  • - Volume 2020
  • - Article ID 6633022
  • - Research Article

MicroRNA-21 Contributes to Acute Liver Injury in LPS-Induced Sepsis Mice by Inhibiting PPARα Expression

Xianjin Du | Miao Wu | ... | Liying Zhan
  • Special Issue
  • - Volume 2020
  • - Article ID 6661642
  • - Research Article

PPARα Agonist WY-14643 Relieves Neuropathic Pain through SIRT1-Mediated Deacetylation of NF-κB

Wanshun Wen | Jinlin Wang | ... | Jun Wang
  • Special Issue
  • - Volume 2020
  • - Article ID 8894525
  • - Research Article

Nonclassical Axis of the Renin-Angiotensin System and Neprilysin: Key Mediators That Underlie the Cardioprotective Effect of PPAR-Alpha Activation during Myocardial Ischemia in a Metabolic Syndrome Model

María Sánchez-Aguilar | Luz Ibarra-Lara | ... | María Esther Rubio-Ruíz
  • Special Issue
  • - Volume 2020
  • - Article ID 8889612
  • - Research Article

Nitric Oxide Mediates Inflammation in Type II Diabetes Mellitus through the PPARγ/eNOS Signaling Pathway

Hua Guo | Qinglan Zhang | ... | Maojuan Wang
  • Special Issue
  • - Volume 2020
  • - Article ID 6527564
  • - Research Article

The Role of Peroxisome Proliferator-Activated Receptors (PPARs) in Pan-Cancer

Runzhi Huang | Jiaqi Zhang | ... | Zongqiang Huang
PPAR Research
 Journal metrics
Acceptance rate44%
Submission to final decision48 days
Acceptance to publication38 days
CiteScore6.300
Journal Citation Indicator0.890
Impact Factor4.964
 Submit

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.